Accelerated atherosclerosis, hyperlipoproteinemia and insulin resistance in long-term survivors of Hodgkin lymphoma during childhood and adolescence.


Journal

Neoplasma
ISSN: 0028-2685
Titre abrégé: Neoplasma
Pays: Slovakia
ID NLM: 0377266

Informations de publication

Date de publication:
11 2019
Historique:
received: 15 01 2019
accepted: 10 04 2019
entrez: 16 7 2019
pubmed: 16 7 2019
medline: 15 8 2019
Statut: epublish

Résumé

Long-term survivors of Hodgkin lymphoma during childhood or adolescence (HL survivors) are at high risk of developing treatment-related late cardiovascular sequelae. In our study we evaluated the presence of modifiable cardiovascular risk factors (hypertension, hyperlipoproteinemia, hyperinsulinemia, obesity), endothelial and inflammatory markers (E-selectin, PAI-1, hs-CRP) and atherosclerotic changes in the common carotid arteries. Assessment was performed in 80 young adult Hodgkin lymphoma long-term survivors at more than 10 years after the potentially cardiovascular toxic anticancer treatment (median age at evaluation 34.7 years; range 24.1-40.9 years). The HL survivors were compared with 83 age- and gender-matched healthy volunteers. The HL survivors showed unfavorable lipid profiles compared to those of healthy controls: triglycerides (p=0.01), total cholesterol (p=0.0004), low density lipoprotein cholesterol (p=0.005). In HL survivors, we found a higher prevalence of hypertension (p=0.004) and insulin resistance - HOMA-IR (p=0.0002). Ultrasonographic examination of both common carotid arteries revealed a higher prevalence of atherosclerotic plaques (p=0.0009) and higher carotid intima-media thickness (p<0.0001) in HL survivors. Markers of oxidative stress (advanced oxidation protein products, oxidized low-density lipoprotein), inflammation (hs-CRP) and endothelial dysfunction (E-selectin, PAI-1) were also higher in HL survivors (p<0.0001, p=0.0002, p=0.0031, p=0.0087, p=0.004, respectively). Adult survivors of Hodgkin lymphoma during childhood and adolescence need closer follow-up with screening of metabolic syndrome components, unfavorable lifestyle factors and early management of these risk factors.

Identifiants

pubmed: 31305124
doi: 10.4149/neo_2019_190115N45
pii: 190115N45
doi:
pii:

Types de publication

Journal Article

Langues

eng

Pagination

978-987

Auteurs

M Cepelova (M)

Department of Pediatric Hematology and Oncology, 2nd Medical Faculty Charles University and University Hospital in Motol, Charles University, Prague, Czech Republic.

J Kruseova (J)

Department of Pediatric Hematology and Oncology, 2nd Medical Faculty Charles University and University Hospital in Motol, Charles University, Prague, Czech Republic.

A Luks (A)

Department of Pediatric Hematology and Oncology, 2nd Medical Faculty Charles University and University Hospital in Motol, Charles University, Prague, Czech Republic.

V Capek (V)

Department of Pediatric Hematology and Oncology, 2nd Medical Faculty Charles University and University Hospital in Motol, Charles University, Prague, Czech Republic.

P Cepela (P)

2nd Internal Clinic, 3rd Medical Faculty Charles University and Kralovske Vinohrady University Hospital, Charles University, Prague, Czech Republic.

J Potockova (J)

2nd Internal Clinic, 3rd Medical Faculty Charles University and Kralovske Vinohrady University Hospital, Charles University, Prague, Czech Republic.

P Kraml (P)

2nd Internal Clinic, 3rd Medical Faculty Charles University and Kralovske Vinohrady University Hospital, Charles University, Prague, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH